

# Sustainability Data Summary 2022





# Targets for a healthy future

**Sustainability at AstraZeneca means harnessing the power of science, innovation and our global reach to build a healthy future for people, society, and the planet.**

We describe our targets and progress on our priorities in this data summary. We are embedding sustainability into everything we do – from the lab to the patient – underpinned by our Values and strategic priorities, right across the enterprise.

The results of our 2021 materiality assessment showed the issues that matter most to AstraZeneca and our stakeholders. It helped us to focus our actions for maximum impact. We have nine focus areas, grouped under three interconnected priority pillars, each with their own targets and commitments.

## External Assurance

Bureau Veritas has provided limited assurance for sustainability activities reported in the Sustainability Data Summary 2022 and in the [Annual Report 2022](#). Details are described in the Letters of Assurance, which are publicly available. Assurance is in accordance with the International Standard on Assurance Engagements (ISAE) 3000 (Revised), Assurance Engagements Other than Audits or Reviews of Historical Financial Information, and with International Standard on Assurance Engagements 3410 – ‘Assurance Engagements on Greenhouse Gas Statements’ (‘ISAE 3410’), issued by the International Auditing and Assurance Standards Board.



### Next generation therapeutics

Advancements in biotechnology have expanded our toolkit of drug modalities. This provides an opportunity to design therapeutics for disease mechanisms previously considered difficult, if not impossible, to target and enables our scientists to pioneer new approaches to drug discovery.

This is a supplement to our [2022 Sustainability Report](#).

We share other aspects of our sustainability activities through other resources:

- [Task Force on Climate-related Financial Disclosures \(TCFD\) Report 2022](#)
- [Sustainability Data Content Index 2022 \(SASB and GRI\)](#)

Coverage for data is global and includes Alexion, which was acquired in 2021, unless otherwise stated.

Where data has not been provided, data was either not available or the methodology has not been assessed for public disclosure.

To evaluate our contribution to achieving the United Nations Sustainable Development Goals (SDGs), we have mapped the SDG targets against our performance. More information about our contribution to the UN SDGs can be found in the [2022 Sustainability Report](#).

## Contents

<b>Access to healthcare</b>	3
<a href="#">Equitable access</a>	3
<a href="#">Affordability and pricing</a>	3
<a href="#">Health system resilience</a>	3

<b>Environmental protection</b>	5
<a href="#">Ambition Zero Carbon</a>	5
<a href="#">Natural resources</a>	9
<a href="#">Product sustainability</a>	11

<b>Ethics and transparency</b>	13
<a href="#">Ethical business culture</a>	13
<a href="#">Inclusion and diversity</a>	15
<a href="#">Workforce safety and health</a>	16

<b>Footnotes</b>	18
------------------	----

# Access to healthcare

## Focus areas: Equitable access, Affordability and pricing, Health system resilience

### Key targets and progress

#### People reached

##### 2025 target

Reach 50 million people (cumulative) through Healthy Heart Africa, Young Health Programme (YHP), and Healthy Lung programmes.<sup>23</sup>

**Status: On plan**

##### 2022 update

More than 44.63 million people reached (cumulative) through Healthy Heart Africa, Young Health Programme and Healthy Lung programmes.<sup>23</sup>

#### Healthcare workers trained

##### 2025 target

Train 170,000 healthcare workers (cumulative) to strengthen health systems throughout the world through our Healthy Heart Africa, Healthy Lung and Phakamisa programmes.

**Status: On plan**

##### 2022 update

More than 126,000 healthcare workers trained (cumulative).<sup>4</sup>

People reached by access to healthcare programmes (cumulative, million) <sup>1</sup>	2020	2021	2022
Healthy Heart Africa <sup>2</sup>	16.675	23.741	32.078
Young Health Programme <sup>3</sup>	5.07	6.25	9.119
<b>Total people reached (all current and historic programmes)<sup>4,5,6,7</sup></b>	<b>25.026</b>	<b>33.427</b>	<b>44.633</b>
Health facilities activated (cumulative)	2020	2021	2022
Healthy Heart Africa <sup>8</sup>	868	958	1,258
<b>Total (all current and historic programmes)<sup>4</sup></b>	<b>3,366</b>	<b>3,599</b>	<b>3,899</b>
Healthcare workers trained (cumulative)	2020	2021	2022
Healthy Heart Africa	7,384	9,004	10,690
<b>Total (all current and historic programmes)<sup>4,5</sup></b>	<b>111,735</b>	<b>124,998</b>	<b>126,684</b>
Young Health Programme (cumulative) <sup>9</sup>	2020	2021	2022
Peer educators trained <sup>10</sup>	118,841	192,318	260,191
Healthcare workers and others trained <sup>11</sup>	20,533	74,025	160,467



Contributing to the [Sustainable Development Goals](#), a universal blueprint for prosperity for people and the planet, now and into the future.

SDG 3 | Good health and wellbeing  
SDG 17 | Partnerships for the goals



AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health <sup>SM</sup> (cumulative) <sup>12</sup>			
	2020	2021	2022
Total dollar amount given in grants (USD, million) <sup>13</sup>	24.7	25.74	26.49
Participants tracked for progress <sup>14</sup>	67,513	70,081	71,732
US-based non-profits funded <sup>15</sup>	58	58	58
Care in Cambodia (cumulative)			
	2020	2021	2022
Women screened in the programme <span style="float: right;">SDG 3.4</span>	6,174	6,416	6,854
Women diagnosed with breast cancer and enrolled in the programme	718	757	889
Units of medicines administered through the programme <sup>16</sup>	295,447	322,456	345,818
Healthcare workers trained <sup>17</sup>	1,292	1,307	1,307
Affordability			
	2020	2021	2022
People reached by Patient Access Programmes (cumulative, million) <sup>18</sup>	10.1	11.55	12.83
Product donation through Patient Assistance Programmes (USD, million) <sup>19</sup>	1,616.2	2,351.5	3,100.2
Philanthropy			
	2020	2021	2022
Disaster relief product donation (total US wholesale acquisition cost value in USD, million)	20.4	23.3	12.10
Total community investment, sponsorships, partnerships and charitable donations (not including Patient Assistance Programmes) (USD, million) <sup>20</sup>	76.2	112.9	108.06
Volunteerism hours	28,440	23,129	15,971
Volunteer (USD equivalent) <sup>22</sup>	–	–	563,053
Non-profit organisations funded by AstraZeneca <sup>21</sup>	1,339	1,220	1,107
Cash contributions (USD, million)	–	–	95.23
In-kind giving (USD, million)	–	–	0.72
Management overheads (USD, million) <sup>22</sup>	–	–	4.61

# Environmental protection<sup>1</sup>

## Focus area: Ambition Zero Carbon

### Key targets and progress

#### GHG reduction

##### 2026 target

Reduce absolute Scope 1 and 2 greenhouse gas emissions by 98% from 2015 base year.

**Status: On plan**

##### 2022 update

Reduced Scope 1 and 2 greenhouse gas emissions by 59.3% since 2015, a reduction of 383 kilotonnes CO<sub>2</sub>e.

Scope 1, 2 and other greenhouse gas emissions (tonnes CO <sub>2</sub> e)	2015	2020	2021	2022
Scope 1 – Road fleet <sup>2</sup>	92,539	44,273	48,346	61,508
Scope 1 – Site energy	175,678	145,318	152,766	134,246
Scope 1 – Site non-energy	37,658	49,869	45,593	49,363
<b>Scope 1 – Total<sup>3</sup></b>	<b>305,875</b>	<b>239,459</b>	<b>246,705</b>	<b>245,117</b>
<b>Scope 2 – Market based<sup>4,5</sup></b>	<b>341,080</b>	<b>32,218</b>	<b>21,135</b>	<b>18,491</b>
<b>Scope 1 &amp; 2 – Total</b>	<b>646,955</b>	<b>271,676</b>	<b>267,841</b>	<b>263,608</b>
<b>SDG 13.2</b>				
Scope 1 & 2 – Intensity (tCO <sub>2</sub> e per million USD of revenue)	24	8	7	5.94
Scope 1 – F-gas emissions (100yr GWP) <sup>6</sup>	37,385	49,670	45,417	49,228
Scope 1 – F-gas emissions (20yr GWP)	64,951	88,504	85,195	93,430
Scope 2 – Location based <sup>4,5</sup>	290,204	228,727	207,003	195,126
Outside of scopes (CO <sub>2</sub> of biological origin)	2,822	10,426	8,919	9,556

  

Solvent (VOC) consumption and emissions from AstraZeneca sites	2015	2020	2021	2022
Consumption (tonnes)	3,106	3,583	3,322	3,361
Emitted (tonnes)	250	178	163	127
Scope 1 GHG emissions (tonnes CO <sub>2</sub> e)	273	199	176	135



Contributing to the Sustainable Development Goals, a universal blueprint for prosperity for people and the planet, now and into the future.

- SDG 6 | Clean water and sanitation
- SDG 7 | Affordable and clean energy
- SDG 12 | Responsible consumption and production
- SDG 13 | Climate action
- SDG 15 | Life on land
- SDG 17 | Partnerships for the goals

## Focus area: Ambition Zero Carbon

### Key targets and progress

#### Road fleet electrification

**2025 target**  
100% electric road fleet by end of 2025.

**Status: Lagging**

**2022 update**  
Our electric vehicle fleet represents 10% of our total fleet, a 527% increase on 2021.  
100% EV target in International<sup>99</sup> markets under review as a result of lack of basic infrastructure in some markets. EV target remains in place for USA, EUCAN<sup>40</sup> and Japan markets, these represent 73% of the overall fleet.

#### Energy consumption

**2025 target**  
Reduce total energy consumption by 10% from 2015 to 2025.

**Status: On plan**

**2022 update**  
Total energy use was 1,636,031 MWh, representing a 14% reduction from the 2015 baseline.

#### Energy productivity

**2025 target**  
Double energy productivity from 2015 to 2025.

**Status: On plan**

**2022 update**  
Energy productivity increased by 89.7% since 2015.

#### Renewable electricity

**2025 target**  
100% renewable electricity consumption globally by 2025.

**Status: On plan**

**2022 update**  
91% of all electricity use came from renewable sources in 2022.

Road fleet	2015	2020	2021	2022
Total vehicles – leased	17,661	17,308	17,766	18,550
Percentage of leased hybrid vehicles	0%	38%	46%	43%
Percentage of leased vehicles that are Plug-in Hybrid Electric Vehicle (PHEV)	0%	7%	9%	10%
EV 100: Battery electric vehicles	0%	0.3%	2%	10%
GHG intensity (gCO <sub>2</sub> per km driven) <sup>7</sup>	165	138	133	151

Energy management	2015	2020	2021	2022
<b>Total energy use (MWh)</b>	<b>1,911,613</b>	<b>1,699,868</b>	<b>1,740,519</b>	<b>1,636,031</b>
EP 100: Energy productivity (million US dollars of revenue per GWh energy consumption) <span style="float: right;">SDG 7.3</span>	14.29	19.23	23.41	27.11
Renewable energy use – electricity and heat (MWh)	131,411	738,734	744,393	740,335
Renewable energy use – electricity and heat	7%	43%	43%	45%
RE100: Renewable electricity use <sup>8</sup> <span style="float: right;">SDG 7.2</span>	14%	87%	88%	91%
Onsite self-generated renewable electricity – on-site solar PV (MWh)	0	5,275	5,929	11,471
Onsite self-generated electricity from non-renewable sources (MWh)	68,445	89,349	93,626	67,285
Imported electricity – renewable (MWh)	122,143	695,599	704,155	697,649
Imported electricity – renewable	15%	98%	100%	99%

## Focus area: Ambition Zero Carbon

### Key targets and progress

Scope 3 Science Based Targets for 2030		2022 (% change from 2019 baseline)	Status
Categories 1 and 2	-46%	+20%	On plan
Category 3	-80%	-28%	On plan
Category 4	-46%	-12%	On plan
Category 5	-46%	-9%	On plan
Category 6	-46%	-53%	On plan
Category 7	-46%	+31%	Lagging
Category 8	-80%	+40%	Lagging
Category 9	Include as data matures	N/A	N/A
Category 11	-95%	-7%	On plan
Category 12	-46%	+18%	Lagging
Category 13	-80%	-66%	On plan

#### SBTi targets

##### 2030 and 2045 target

Reduce absolute Scope 3 GHG emissions 50% by 2030 and 90% by 2045, from a 2019 base year.

**Status: On plan**

##### 2022 update

Total Scope 3 increased by 8.6% from a 2019 baseline and Scope 3 intensity reduced by 28.1%. Significant increase in use of primary data and suppliers setting Science Based Targets will support future absolute emissions reductions towards 2030 target.

#### Data quality

##### 2025 target

Increase the share of primary activity data in Scope 3 reporting.

**Status: On plan**

##### 2022 update

38% of data used to calculate scope 3 came from primary sources. Significant improvements have been made in primary data percentage and these changes have been applied back to the baseline year to enable fair comparison of performance. Actual primary data level in 2019 was 20%.

GHG Protocol Scope 3 category (tonnes CO <sub>2</sub> e)		2019	2020	2021	2022
Category 1	Purchased goods and services <sup>9</sup>	3,865,091	4,005,685	4,475,533	4,665,237
Category 2	Capital goods	76,941	75,914	88,762	76,863
Category 3	Fuel and energy related (not Scope 1 or 2)	83,332	55,252	53,273	60,128
Category 4	Upstream transportation and distribution	248,112	218,144	228,675	218,745
Category 5	Waste generated in operations	21,027	20,204	20,027	19,102
Category 6	Business travel <sup>10</sup>	326,653	83,806	82,385	154,545
Category 7	Employee commuting	30,275	37,646	41,293	39,567
Category 8	Upstream leased assets	41,771	57,628	55,780	58,344
Category 9	Downstream transportation and distribution <sup>11</sup>	132,083	130,882	127,207	117,061
Category 10	Processing of sold products	Assessed: Not relevant			
Category 11	Use of sold products	1,012,732	978,895	818,582	945,209
Category 12	End-of-life treatment of sold products <sup>12</sup>	21,138	19,933	22,234	24,868
Category 13	Downstream leased assets	25,119	5,947	3,975	8,463
Category 14	Franchises	Assessed: Not relevant			
Category 15	Investments	Assessed: Not relevant			
<b>Total scope 3</b>	SDG 13.2	5,884,273	5,689,936	6,017,727	6,388,133

GHG Protocol Scope 3 category	2019	2020	2021	2022
Scope 3 intensity (tCO <sub>2</sub> e per million USD of revenue)	200.32	174.07	147.66	144.04
Scope 3 based on primary data <sup>13</sup>	39%	33%	29%	38%

## Focus area: Ambition Zero Carbon

### Key targets and progress

#### Supply chain engagement

##### 2025 target

95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have science-based targets (SBTs).

**Status: On plan**

##### 2022 update

The percentage of supplier by spend with verified SBTs are: 12% for categories 1 and 2, 19% for category 4 and 14% for category 6. More suppliers have submitted SBTs for verification.

#### Use of products

##### 2025 target

Launch a next-generation inhaler to treat asthma and Chronic Obstructive Pulmonary Disease (COPD) containing a near-zero Global Warming Potential (GWP) propellant.

**Status: On plan**

##### 2022 update

In 2022, project milestones achieved included the Phase III investment decision, initiation of pivotal studies, first delivery of commercial grade propellant from Honeywell's new large scale Good Manufacturing Practice (GMP) facility and positive regulatory interactions globally.

Supply chain engagement (% spend with verified SBTs) <sup>14</sup>	2020	2021	2022
Category 1 – Purchased goods and services	–	7%	12%
Category 2 – Capital goods	–	–	–
Category 4 – Upstream transportation and distribution	–	–	19%
Category 6 – Business travel	–	–	14%

  

Other Scope 3 metrics <sup>15</sup>	2020	2021	2022
Upstream transportation and distribution Air2Sea&Rail (% tonne.km)	78%	73%	74%
Upstream transportation and distribution Air2Sea&Rail (% volume)	70%	64%	65%



## Focus area: Natural resources

### Key targets and progress

#### Water usage

##### 2025 target

Reduce water use by 20% below the 2015 baseline.<sup>41</sup>

**Status: On plan**

##### 2022 update

Water footprint was 3.75 million m<sup>3</sup>, a 18.7% reduction from 2015.

#### Waste reduction

##### 2025 target

Reduce waste by 10% below the 2015 baseline.

**Status: On plan**

##### 2022 update

Total waste was 25,493 tonnes, representing a decrease of 18.6% from 2015.

Water use within site water footprint, excluding non-contact cooling water	2015	2020	2021	2022
Municipal (million m <sup>3</sup> )	3.83	3.12	3.16	3.25
Groundwater (million m <sup>3</sup> )	0.77	0.66	0.66	0.45
Rainwater (million m <sup>3</sup> )	0.00	0.05	0.05	0.04
<b>Total (million m<sup>3</sup>)</b>	<b>4.61</b>	<b>3.83</b>	<b>3.87</b>	<b>3.75</b>
Chemical oxygen demand – effluent leaving our sites (tonnes)	206	428	615	486
Sites in water stewardship programme	–	–	6	6

Non-contact cooling water <sup>16</sup>	2015	2020	2021	2022
Direct from fresh surface water – volume fully returned after use (million m <sup>3</sup> ) <sup>17</sup>	9.48	12.16	10.34	8.49

Water use by water scarcity rating for sites with over 10,000 m <sup>3</sup> water per year (including non-contact cooling water) <sup>18</sup> (m <sup>3</sup> )	2020	2021	2022
High stress rating	60,012	57,476	49,466
Medium stress rating	58,946	49,108	53,461
Low stress rating <sup>19</sup>	15,814,861	14,012,745	12,073,903
Percentage of water consumption by AstraZeneca in low stressed areas	99.3%	99.2%	99.2%

Waste management <sup>20</sup>	2015	2020	2021	2022
<b>Total waste (tonnes)</b>	<b>31,316</b>	<b>30,791</b>	<b>28,619</b>	<b>25,493</b>
Total recycling (tonnes)	14,060	12,183	10,351	9,399
Total recycling as a percentage of total waste	45%	40%	36%	37%
Total waste to landfill (tonnes)	2,265	1,049	906	596
Waste avoided – by-product sold (tonnes)	–	–	999	2,129

Non-hazardous waste <sup>20</sup>	2015	2020	2021	2022
<b>Total non-hazardous waste (tonnes)</b>	<b>22,294</b>	<b>20,101</b>	<b>18,278</b>	<b>15,514</b>
Non-hazardous waste recycled (tonnes)	13,326	11,161	9,435	8,551
Non-hazardous waste to landfill (tonnes)	2,238	1,021	859	570

## Focus area: Natural resources

### Key targets and progress

#### Investing in nature

##### 2025 target

Plant and maintain 50 million trees by 2025.

**Status: On plan**

##### 2022 update

7,067,529 trees were planted through AZ Forest in 2022. The total is 10,516,473 since 2020.

#### Raw materials

##### 2025 target

All 12 key materials within our Raw Materials Responsible Sourcing Framework have sustainability action plans in place.

**Status: On plan**

##### 2022 update

Through partnership with Supply Shift, we have improved our understanding of our timber sourcing and work has begun to apply this model to other critical raw materials, including palm oil.

#### Green labs

##### 2025 target

All of our sites with labs operate My Green Labs.<sup>41</sup>

**Status: On plan**

##### 2022 update

84 labs accredited with 'My Green Labs' certification; including 15 QC labs and 69 R&D labs across 24 sites.

Hazardous waste <sup>20</sup>	2015	2020	2021	2022
<b>Total hazardous waste (tonnes)</b>	<b>8,822</b>	<b>10,690</b>	<b>10,341</b>	<b>9,978</b>
Hazardous waste recycled (tonnes)	734	1,023	916	848
Hazardous waste to landfill (tonnes)	27	28	47	26

Green Labs Programme	2020	2021	2022
Number of valid My Green certifications	43	56	84
Employees engaged in My Green Lab Programme <sup>21</sup>	962	943	2333

Supply chain – Environmental footprint for critical direct suppliers <sup>22,23</sup>	2020	2021	2022
API category – total waste (thousand tonnes)	66	36	40.1
Formulation & Packaging (F&P) category – total waste (thousand tonnes)	3	4	3.7
API category – water use (million m <sup>3</sup> )	1.4	1.2	0.9
F&P category – water use (million m <sup>3</sup> )	0.3	0.3	0.2

Investing in nature		2020	2021	2022
AZ Forest: Trees planted	SDG 15.2	337,807	3,111,137	7,067,529

## Focus area: Product sustainability

### Key targets and progress

#### PIE leadership

##### 2025 target

Lead the industry to manage Pharmaceuticals in the Environment (PIE).

**Status: On plan**

##### 2022 update

Nine peer-reviewed papers published, including articles on forward looking solutions to sustainable healthcare and minimising the use of animal studies in environmental assessments.

Continued to lead on transparency of environmental data associated with our products through our dashboard. We took a leading role within our industry on the publication and promotion of the extended Environmental Risk Assessment and Technical Guidance on manufacturing effluent management.

#### Resource efficiency

##### 2025 target

Ensure 90% of total syntheses meet resource efficiency targets at launch.<sup>42</sup>

**Status: Lagging**

##### 2022 update

Since 2015, 67% of projects (six of nine) have met defined resource efficiency targets at launch. In 2022 we have integrated data from our monoclonal antibody (mAb) products for the first time but one mAb product launched in 2022 narrowly missed the target. Although there were no in-scope small molecule API products launched, we achieved a PMI reduction of 23% across the late stage project portfolio.

#### Sustainable sourcing

##### 2022 target

Ensure 95% of paper-based product packaging materials used are supplied from sustainable sources.

**Status: On plan**

##### 2022 update

In 2022, we conducted a comprehensive survey of all our paper-based packaging suppliers. We determined that 97.5% of materials used in our products were sourced from sustainably managed forests, achieving our sustainable packaging target.

Safe active pharmaceutical ingredients (API) discharges <sup>22,24</sup>		2020	2021	2022
Safe API discharges for AstraZeneca sites <sup>25</sup>	SDG 6.3	100%	100%	100%
Safe API discharges from suppliers <sup>26,27</sup>	SDG 6.3	94%	91%	92%
Number of safe API discharge supplier assessments completed		75	75	66
Resource efficiency		2020	2021	2022
Small molecule API syntheses that meet resource efficiency at launch <sup>28</sup>	SDG 12.2	67%	75%	75%
Monoclonal antibody syntheses that meet resource efficiency target at launch <sup>29</sup>	SDG 12.2	—	75% <sup>30</sup>	60%
<b>Total syntheses that meet resource efficiency target at launch</b>		<b>—</b>	<b>75%</b>	<b>67%</b>
Product value chain environmental impact		2020	2021	2022
Number of key products scored against Product Sustainability Index <sup>31</sup>		—	4	9
Number of key products with lifecycle assessment completed <sup>31,32</sup>		—	—	14
Paper-based product packaging materials supplied from sustainable sources <sup>33</sup>	SDG 15.2	—	—	97.5%



### Additional metrics

Compliance summary	2020	2021	2022
Prosecutions <sup>34</sup>	0	0	0
Enforcement actions <sup>35</sup>	0	1	0
Regulatory warnings/alerts <sup>36</sup>	0	1	2
Other environmental compliance matters <sup>37</sup>	3	1	1
Awaiting regulator outcome or AstraZeneca investigation ongoing	0	2	1
Significant environmental violations <sup>38</sup>	0	0	0
Financial penalties relating to above (USD)	0	0	0

# Ethics and transparency

## Focus area: Ethical business culture

### Key targets and progress

#### Business ethics

##### 2025 target

Maintain 100% of active employees trained on the Code of Ethics.

**Status: On plan**

##### 2022 update

100% of active employees trained on the Code of Ethics in 2022.

#### 'Speak up' culture

##### 2025 target

Ensure AstraZeneca has a 'speak up' culture.

**Status: On plan**

##### 2022 update

83% of employee survey respondents feel we have a 'speak up' culture.

#### Human rights survey

##### 2025 target

Improve the AstraZeneca global biennial human rights survey results and use the Fair Wage Network data to more robustly assess our performance against local living wage data.

**Status: On plan**

##### 2022 update

The biennial human rights survey has been completed by 74 countries and action plans are in progress. The analysis of Fair Wage Network data has enabled us to ensure we continue to pay a fair living wage globally.

Business ethics	2020	2021	2022
Active employees trained on Code of Ethics <sup>1</sup>	100%	100%	100%
Percentage of employees who feel we have a 'speak up' culture <sup>2</sup>	84%	83%	83%
Concerns reported through the company helpline in commercial regions (per thousand employees) <sup>3</sup>	6.8	6.3	7.5
Instances of non-compliance with the Code of Ethics in commercial regions (per thousand employees) <sup>3</sup>	49.1	50.9	55.6
Corrective actions taken in commercial regions (per thousand employees) <sup>3</sup>	71.3	83.9	115.5
Employees terminated or asked to leave due to non-compliance in commercial regions (per thousand employees) <sup>3</sup>	2.5	2.2	3.2

Clinical trials transparency (all cumulative)	2020	2021	2022
Studies shared with external research teams	160	165	228
Requests we responded to from external researchers using our clinical trials portal <sup>4</sup>	199	255	313
Publicly available trial summaries	173	245	312
Clinical document packages published by EMA and Health Canada	9	13	14

Political donations	2020	2021	2022
Contributions to U.S. national political organisations, state-level political party committees and to campaign committees (USD, million)	1.02	1.14	1.86

Human rights	2020	2021	2022
Countries that completed the Human Rights survey <sup>5</sup>	72	—	74
Countries that have a relationship with trade unions <sup>5</sup>	56%	—	45%
Number of employees who receive Modern Slavery awareness training annually	72,173	79,138	80,536



Contributing to the Sustainable Development Goals, a universal blueprint for prosperity for people and the planet, now and into the future.

SDG 3 | Good health and wellbeing  
 SDG 5 | Gender equality  
 SDG 8 | Decent work and economic growth  
 SDG 17 | Partnerships for the goals

## Focus area: Ethical business culture

### Key targets and progress

#### Positive sourcing programme

##### 2025 target

Our Positive Sourcing Programme aims for 100% ethical spend by embedding sustainability into end-to-end processes.

**Status: On plan**

##### 2022 update

All suppliers are required to work in accordance with our Code of Ethics and Expectations of Third Parties. 53% of our spend with suppliers is now with companies who have been assessed by EcoVadis to have an acceptable ESG rating (45 or more).

Data privacy	2020	2021	2022
Privacy impact assessments	1,884	2,054	2,161
Data subject rights	218	185	240
Privacy regulatory impact assessments	2	3	0
Dedicated on-line privacy training <sup>6</sup>	36,295	55,363	65,521
Transfer impact assessments (TIAs) <sup>7</sup>	—	—	2,728
Responsible supply chain	2020	2021	2022
Total supplier assessments <sup>8</sup>	16,197	13,633	9,481
High-risk supplier audits <sup>9</sup>	48	37	42
Percentage of suppliers by spend assessed by EcoVadis <sup>10</sup>	—	—	60%
Percentage of suppliers by spend assessed by EcoVadis that achieve >45 <sup>10</sup>	—	—	53%
Critical manufacturing suppliers that disclose their energy, waste and water footprint (%)	61%	75%	94%
PSCI environmental sustainability assessments completed	66	70	67
Animal use standards	2020	2021	2022
In-house research (number of animals)	74,684	93,511	100,803
External contract research (number of animals)	51,625	58,826	55,455
<b>Total number of animals</b>	<b>126,309</b>	<b>152,337</b>	<b>156,258</b>
Council for Science and Animal Welfare (C-SAW) Global 3Rs Awards (number of awards)	—	3	3
Signatory to the Concordat on Openness on Animal Research in the UK	Yes	Yes	Yes
Human biological samples	2020	2021	2022
Human foetal tissue (hFT) supplier assessments	4	0	1
hFT suppliers approved to date	60%	60%	64%
hFT projects approved and progressed to date	36%	36%	46%
Active projects using hFT	3	2	3
hESC projects approved <sup>11</sup>	100%	100%	100%
Active projects using human embryonic stem cells (hESC)	7	13	17

## Focus area: Inclusion and diversity

### Key targets and progress

#### Gender equality

##### 2025 target

Reach gender equality in management positions.

**Status: On plan**

##### 2022 update

49.5% of senior middle management roles are occupied by women.

#### Supplier diversity

##### 2025 target

Launch supplier diversity programmes in 10 new countries (outside of the United States).

**Status: On plan**

##### 2022 update

Programmes launched in total of seven countries outside of USA, with one more country, Sweden, launched in 2022.

Inclusion and diversity	2020	2021	2022
Women representation of AstraZeneca employees	50.5%	51.8%	52.9%
Women in management – All management levels <sup>12</sup>	SDG 5.5 42.5%	44.3%	45.5%
Women in management – Senior middle management <sup>13</sup>	SDG 5.5 46.9%	48.1%	49.5%
Women in management – Executive management <sup>14</sup>	SDG 5.5 39.7%	39.5%	41.7%
Women representation on Senior Executive Team (SET) <sup>15</sup>	SDG 5.5 33.3%	41.7%	41.7%
Women representation on Board of Directors	SDG 5.5 35.7%	38.5%	38.5%
Share of women in STEM-related positions <sup>16,17</sup>	37.8%	38.4%	39.8%
Share of women in management positions in revenue-generating functions <sup>19</sup>	43.1%	45%	46.3%
Share of women in junior management positions, i.e. first level of management <sup>17,18</sup>	40.7%	43.4%	44.5%
Leadership within country of origin: emerging markets and Japan in roles that report to our SET (emerging markets and Japan)	18.4%	18.4%	17.7%
Ethnic minority representation for US employees <sup>20</sup>	30.6%	32.1%	35.7%
Percentage of full-time employees age < 30	–	–	17.1%
Percentage of full-time employees age 30-50	–	–	62.1%
Percentage of full-time employees age >50	–	–	20.8%
Countries with supplier diversity programmes	4	7	8

## Focus area: Workforce safety and health

### Key targets and progress

#### Workforce safety

##### 2025 target

75% reduction in total injury rate from 2015 baseline.<sup>27</sup>

##### 2022 update

72% reduction in reportable injury rate since 2015.

**Status: On plan**

#### Driver safety

##### 2025 target

55% reduction in collisions per million kilometres driven from 2015 baseline.<sup>27</sup>

##### 2022 update

49% reduction in collision rate since 2015.

**Status: On plan**

Workforce safety and health <sup>21</sup>	2020	2021	2022
Total reportable injury rate (per million hours worked) (employees) <sup>22</sup>	0.63	0.56	0.49
Alexion – Total reportable injury rate (per million hours worked) (employees) <sup>22</sup>	0.4	0.62	0.7
Collisions (per million kilometres driven) <sup>22</sup> <span style="float: right;">SDG 3.6</span>	2.21	2.46	2.09
Occupational illness rate (per million hours worked) (employees) <sup>22</sup>	0.69	0.53	0.3
Lost time injury rate (per million hours worked) (employees) <sup>22</sup>	0.42	0.35	0.15
Alexion – Lost time injury rate (per million hours worked) (employees) <sup>22</sup>	0	0.47	0.6
Lost time injury rate (per million hours worked) (construction contractors) <sup>23</sup>	1.48	3.12	1.24
Fatalities (employees) <sup>22,24</sup> <span style="float: right;">SDG 8.8</span>	0	2	0
Alexion – Fatalities (employees) <sup>22</sup> <span style="float: right;">SDG 8.8</span>	0	0	0
Fatalities (contractors) <sup>22</sup> <span style="float: right;">SDG 8.8</span>	0	0	0





Employee satisfaction	2020	2021	2022
Employee perception of the opportunities for personal development and growth	84%	82%	83%
Employees that have at least one quality development discussion with their line manager	88%	89%	89%
Employee belief in our strategy	92%	87%	89%
Employee perception of AstraZeneca as a "Great Place to Work" survey score	89%	85%	86%
Sustainability engagement survey score	87%	84%	87%

Employee recruitment and retention	2020	2021	2022
Employees that have a development plan	52%	79%	77.2%
Senior vacancies filled by internal candidates <sup>25</sup>	60%	88%	85.7%
Overall promotion rate	7.4%	8.2%	8.3%
Voluntary employee turnover – recent hires	14.7%	20.6%	13.1%
Voluntary employee turnover – total	9.7%	13.9%	10.7%
Employee turnover rate	–	–	18.9%
Organisational structure – percentage of employees within six management steps of the Chief Executive Officer (CEO)	63%	64%	55.8%

Product safety	2020	2021	2022
FDA Class I Recall	0	0	0
FDA Class II Recall	1	0	0
FDA Class III Recall	2	0	0
Total FDA recalls	3	0	0
Total FDA observations	0	9	15
Total FDA inspections	1	3	4
Total inspections from all health authorities	14	34	50
Unique health authorities completing inspections	8	22	24

Quality manufacturing	2020	2021	2022
Internal quality audits of AstraZeneca suppliers	243	379	501
Internal quality audits of AstraZeneca sites <sup>26</sup>	50	46	61

# Footnotes

## Access to healthcare

1. People 'reached' is defined per programme, depending on the operations of specific programmes.
2. People reached through Healthy Heart Africa refers to total people screened.
3. People reached through Youth Health Programme (YHP) refers to direct beneficiaries, primarily young people that the YHP has had direct contact with or engaged in a community activity. This includes in-person events as well as digital events and trainings where there has been direct contact with people.
4. Healthy Lung Programme is considered a historic programme, which contributes: 114,709 healthcare workers (HCW) trained since 2010, 1.807 million people reached and 2,641 health facilities activated. Data from Healthy Lung Programme was not assured in 2021 and there is no data reported for 2022.
5. Phakamisa is considered a historic programme, which contributes: 1.629 million reached and 1,285 HCWs and volunteers trained. Phakamisa has reported no activities since end of 2020, due to changes in programme strategy.
6. People reached through Health Lung Programme refers to: educated, diagnosed and treated through Healthy Lung Asia, and educated and people diagnosed through Healthy Lung Mexico and for programmes in Saudi Arabia, Gulf and Egypt.
7. 2021 data has been restated in 2022.
8. Healthcare facilities activated for Healthy Heart Africa refers to when a healthcare facility is equipped and ready to implement.
9. People 'trained' is defined per project, depending on the specific operations.
10. Peer Educators through YHP refers to young people that are capacitated by the YHP to train their peers on Non-Communicable Disease (NCD) risk factors.
11. Healthcare workers and others trained through YHP refers to people trained with NCD-prevention information, such as Healthcare Professionals (HCPs), parents, teachers and community leaders/stakeholders. Excludes Peer Educator totals.
12. The AstraZeneca (HealthCare) Foundation is a Delaware, United States, nonprofit corporation and a 501(c)(3) entity, separate from AstraZeneca Pharmaceuticals, organised for charitable purposes including to promote public awareness and education of healthcare issues and support eligible nonprofit organisations in alignment with its mission.
13. Total amount of dollars (USD millions) given by the AstraZeneca Foundation to eligible nonprofit organisations through its Connections for Cardiovascular HealthSM (CCH) and CCH Next Generation programmes for innovative, community-based programmes designed to address cardiovascular disease within the United States (US) and its territories. Numbers are rounded, typically, to the nearest million.
14. Number of unique CCH and CCH Next Generation funded programme participants for whom there is at least one pre- and post-survey data point, baseline and follow-up clinical and/or behavioural measure, or other clear outcome data as self-reported from funded organisations. Individuals included in this number are only counted once, even if they participate across programme years.
15. Unduplicated number of nonprofit organisations with a 501(c) designation, or public schools, government entities or municipal institutions that are eligible to accept tax-deductible, charitable contributions that were funded by the AstraZeneca Foundation's CCH or CCH Next Generation programmes.
16. A number of medicines are administered through the programme. This includes medicines donated by AstraZeneca as well as those procured using funds donated for the programme.
17. Data was not assured in 2022 so no progress has been reported.
18. As of the time of publishing the report, there was an 88% response rate from global markets. Cumulative reporting means the remainder will be captured in next year's reporting and that people reached may not be unique individuals.
19. These patient assistance programmes use fully donated products without expectation of payment from the patient for any portion or to access the programme.

20. Methodology update in 2022 means total community investments refers to payments completed within the financial year.
21. Includes financial donations, in-kind donations, product donations.
22. Calculations for management overheads (USD equivalent) and volunteer (USD equivalent) are calculated based on an assumption of days worked and average salary calculations.
23. Progress towards target includes Phakamisa, a historic programme.

## Environmental protection

1. Regular review of the data is carried out to ensure accuracy and consistency. This has led to changes in the data from previous years across Environment Protection. Material changes are outlined with additional footnotes.
2. Calculation of GHG emissions from road fleet in 2022 has been calculated using primary data (volume of fuel purchased where available) and accounts for 97% of total road fleet related GHG footprint. GHG emissions prior to 2022 have been reported exclusively using average fleet intensity values from manufacturer published data.
3. Included are greenhouse gases (GHGs) from direct fuel combustion, process and engineering emissions at our sites and from fuel used in our vehicle fleet.
4. GHGs from imported electricity are calculated using the GHG Protocol Scope 2 Guidance (January 2015) requiring dual reporting using two emissions factors for each site – market-based and location-based. Location-based factors are the grid average emissions factor for the country (or sub-region in the US) where a site is located. Market-based factors are more specific to the site and local energy market, taking account of the residual energy mix a site is sourcing electricity from, and any certified renewable electricity purchased by a site. Market and Location based emissions have been calculated for our sites and our owned and leased vehicle fleet.
5. Electricity, heat, steam and cooling purchased for own use at AstraZeneca sites and also electric charging of AstraZeneca owned and leased vehicles.
6. F-gas emissions using 100yr GWP from IPCC AR4 are included within reporting of Scope 1 emissions.
7. This figure is based on the AZ fleet (18,058 vehicles) only as distance travelled is not available for the Alexion vehicle fleet.
8. Proportion of total electricity consumption including imported, self-generated from on-site solar PV and combined heat and electricity installations.
9. Methodology update to transition relevant procurement spend categories from a spend based emissions database to product lifecycle assessment (LCA) data, thereby improving accuracy. Additional small improvements have been made to spend based methodology emission factors. Changes have been applied to historic data.
10. Methodology update from spend based emissions to primary activity hotel and Alexion grey fleet data.
11. Methodology update to use production data and updated assumptions to account for the footprint associated with patient travel. High uncertainty of this category means further review is ongoing to improve the methodology.
12. Methodology update to transition from spend based approach to emissions calculated using production and LCA data.
13. Primary data is defined as either activity-based data or supplier provided data.
14. Alexion data has been incorporated from 2022 onwards.
15. Alexion not included.
16. Non-contact cooling water reported separately and is excluded from water efficiency target to increase focus on our more material freshwater use elsewhere in our site network.
17. Non-contact cooling water use is relevant to one of our sites only – Södertälje, Sweden, where it is used to minimise the energy demand and carbon emissions from cooling. Per extensive environmental risk assessment evaluations, there is minimal impact from the use of water from the lake – chemical properties of the water are unchanged, there is no evaporative loss and it is fully returned to the same water body at temperatures below 20°C in line with permit supported by environmental risk assessment.

18. WWF's Water Risk Filter is used to complete regular site water risk assessment.
19. Restated to include non-contact cooling water, which was previously excluded from reporting.
20. Waste from construction and demolition is excluded from the data reported.
21. Number of employees completing the My Green Lab Survey.
22. Data collected one year in arrears so data in 2022 column relates to environmental footprint in 2021 and so on.
23. Covering >90% spend.
24. Scope is 54 APIs for which data is available to calculate safe API discharge limits and based on 2021 manufacture and formulation activities.
25. One discharge assessment at a single timepoint (1/44 measurements) marginally exceeded the safe discharge target (failure in vacuum system and water use reduction causing high concentration in effluent, vacuum promptly repaired upon identification of fault, all other timepoints measurements were within safe discharge targets).
26. One of 66 API discharges marginally exceeded the safe discharge target (RQ = 1.3 based on application of additional marine assessment factor of 10).
27. Five of 66 API discharge assessments from suppliers were not submitted
28. Scope is for products launched with new active pharmaceutical ingredient (API) and the manufacturing process developed in-house.
29. Scope is for products launched with a new monoclonal antibody drug substance and the manufacturing process developed in-house. Alexion brands excluded.
30. Resource efficiency data for monoclonal antibodies launched in 2021 validated and reported in 2022.
31. Key products are prioritised on an annual basis by our Global Supply Chain and Strategy organisation.
32. Cradle to grave streamlined life cycle assessment across the product value chain measuring five environmental impact areas.
33. Data reported for 2022 is for calendar year 2021 and based on weight supplied. Scope includes primary, secondary, and tertiary packaging. Alexion brands excluded.
34. Prosecution: successful or pending legal action taken in a civil or criminal court against AstraZeneca.
35. Enforcement action: any formal administrative or judicial enforcement proceeding, notices of violation or similar action by a regulator that requires the company to do, or not do, something.
36. Regulatory warning/alert: any formal written warning or alert received from a regulator stating that the company is in violation of an applicable SHE requirement, which if not corrected or repeated, could incur prosecution or enforcement action.
37. Other environmental compliance matter: any less significant environmental compliance matter not included above.
38. Significant environmental violation: those that result in a fine >\$10,000.
39. The International region consists of the following markets: Georgia, Ukraine, India, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam, Argentina, Central America, Caribbean, Peru, Ecuador, Chile, Mexico, Colombia, Venezuela, Egypt, United Arab Emirates, Bahrain, Qatar, Oman, Kuwait, Iran, Iraq, Jordan, Lebanon, Libya, Sudan, Yemen, Morocco, Saudi Arabia, South Africa, Kenya, Nigeria, Turkey, Kazakhstan, Russia, China, New Zealand and Brazil.
40. The EUCAN region consists of the following markets: Netherlands, Sweden, Norway, Denmark, Finland, France, United Kingdom, Spain, Ireland, Belgium (including Luxembourg), Slovenia, Croatia, Portugal, Switzerland, Bulgaria, Estonia, Latvia, Serbia, Austria, Slovakia, Greece, Romania, Czech Republic, Hungary, Israel, Italy, Lithuania, Poland, Germany and Canada.
41. Target updated in 2022 to reflect increased ambition before 2025. Convergence of two targets communicated in 2020 and 2021 for small molecule syntheses and biologics products.

## Ethics and transparency

1. We define our 100% complete statistic by saying all active employees on the day of roll out (in this case 16/17th October) must complete the course. Active employees are those not impacted by variables such as parental leave, long-term sickness and garden leave.
2. 'Speak up' question in the internal survey changed from: "I feel comfortable to speak up and express my opinion at work" in 2020 and to "I feel comfortable to speak my mind and express my opinion at work" in 2021 and 2022.
3. Compliance rates were calculated based on number of employees in commercial regions as of 1st of January 2023.
4. 2021 data has been restated.
5. No data in 2019 and 2021 as the human rights survey is biennial.
6. Number of generic, mandatory trainings completed.
7. Data collected from September 2021 when TIA regulation was launched by the EU Commission.
8. Total supplier assessments refer to number of Third-Party Risk Management assessments.
9. 2022 number of high-risk supplier audits includes 37 onsite audits and 5 remote assessments in 2022.
10. Spend based on data from 2021.
11. 100% approval rate reflects self-selection effect that only high relevance projects with a good justification come forward for approval.
12. All management refers to staff Manager level.
13. Senior middle management refers to director level and above.
14. Executive management refers to senior directors and above.
15. Data includes Katarina Ageborg, who announced retirement in 2022 effective from 2023.
16. Refers to percentage share of total science, technology, engineering and math (STEM) positions.
17. Alexion not included.
18. Refers to percentage share of total junior management positions.
19. Refers to percentage share of all managers in revenue-generating functions, such as sales. Excludes supporting functions (HR, IT, Legal etc.)
20. Alexion included from 2022.
21. The inclusion criteria for injuries and occupational illnesses indicators are aligned with the US Occupational Safety and Health Administration (OSHA) Record Keeping Rule.
22. Workforce safety and health for AstraZeneca and Alexion is reported separately. AstraZeneca represents 94% of total workforce, Alexion represents 6% of total workforce.
23. Construction contractors are defined as workers employed and managed by third-party construction/ engineering companies, working on AstraZeneca capital projects.
24. Sadly, an AstraZeneca driver was involved in a vehicle accident that resulted in fatal injuries to a member of the public in the United States in December of 2021 (the investigation finalised in early 2022).
25. Senior Vacancies defined as SET -1 Level (Internal Promotion + Internal Change of Roles)/ (Internal Promotion + Internal Change of Roles + External Hires)
26. For 2022 includes 45 AstraZeneca sites, of which 17 are marketing sites, and 16 Alexion sites.
27. Target excludes Alexion.